secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001104659-25-062058
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026
--------------------------------------------------------------------------------

- Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.
- Plans simultaneous IND submissions to FDA and Korea's MFDS in H2 2026; site activations and patient screening start early 2027.
- Partnered with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trial in NSCLC, including 3+3 dose-escalation and PD-1/PD-L1 combination arms.
- Preclinical combination data with PD-1/PD-L1 inhibitors showed increased complete response rates versus monotherapy.
- Engineered epitope selectivity and Fc modifications designed to avoid anemia/thrombocytopenia that halted earlier CD47 programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/0001104659-25-062058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/tm2518817d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-062058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer